Product Name: Human KDR / VEGFR2 Antibody (Ramucirumab, Research Use)
Catalog Number: NBR-0089
Target Name: KDR / VEGFR2
Trade Name: Ramucirumab
Antibody Drug Description: Ramucirumab (Cyramza) is the first FDA-approved agent to reduce tumor angiogenesis by targeting the extracellular domain of the VEGFR. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: KDR / VEGFR2
Synonyms: VEGFR2; FLK1; Vascular Endothelial Growth Factor Receptor 2; VEGFR; CD309
Target Description: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. 
Ensembl: ENSG00000128052
Uniprot: P35968